Evidence map›Paper›PMID 40893955›Full record

ArticleACS central science2025

Carbamate Prodrugs Restrict

Jishnu Sankar, Manish Kumar Bajpai, Anjali Chauhan, Ravi Maddheshiya, Nidhi Sharma, Aditya Sharma, Yashwant Kumar, Dinesh Mahajan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS central science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jishnu SankarCentre for Drug Discovery, BRIC-Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India.
Manish Kumar BajpaiCentre for Drug Discovery, BRIC-Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India.
Anjali ChauhanCentre for Drug Discovery, BRIC-Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India.
Ravi MaddheshiyaCentre for Drug Discovery, BRIC-Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India.
Nidhi SharmaCentre for Drug Discovery, BRIC-Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India.
Aditya SharmaCentre for Drug Discovery, BRIC-Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India.
Yashwant KumarCentre for Drug Discovery, BRIC-Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India.
Dinesh MahajanCentre for Drug Discovery, BRIC-Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India.ORCID https://orcid.org/0000-0002-7939-9506

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isoniazid (INH), an important first-line drug in tuberculosis (TB) treatment, faces significant challenges primarily due to hepatotoxicity and peripheral neuropathy as major side effects. These adverse effects often lead to poor patient compliance and treatment dropouts. The INH's

Identifiers

PMID40893955
PMCPMC12395308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.